Sleep Medicine
Volume 1, Issue 3 , Pages 231-243 , 1 July 2000

Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsy

  • Merrill M Mitler

      Affiliations

    • Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA, USA
    • Corresponding Author InformationCorresponding author. Sleep Disorders Center, Scripps Clinic Research Foundation, 9834 Genesee Avenue, Suite 328, La Jolla, CA 92037, USA. Tel.: +1-619-784-9295; fax: +1-619-657-0559
    • ,
  • John Harsh

      Affiliations

    • Sleep Disorders Center, Forrest General Hospital, Hattiesburg, MI, USA
    • ,
  • Max Hirshkowitz

      Affiliations

    • Sleep Diagnostic Center, VA Medical Center, Houston, TX, USA
    • ,
  • Christian Guilleminault

      Affiliations

    • Stanford Sleep Disorders Clinic, Stanford, CA, USA
    • ,
  • for the U.S. Modafinil in Narcolepsy Multicenter Study Group

Received 23 February 2000 ,Revised 27 March 2000 ,Accepted 28 March 2000.

References 

  1. Hublin C, Partinen M, Kaprio J, Koskenvuo M, et al.  Epidemiology of narcolepsy. Sleep. 1994;17:S7–S12
  2. Guilleminault C, Mignot E, Grumet FC. Familial patterns of narcolepsy. Lancet. 1989;2:1376–1379
  3. Mignot E, Lin X, Arrigoni J, Macaubas C, et al.  DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and Black Americans. Sleep. 1994;17:S60–S67
  4. Broughton R, Ghanem Q, Hishikawa Y, Sugita Y, et al.  Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Can J Neurol Sci. 1981;8:299–304
  5. Kales A, Soldatos CR, Bixler EO, Caldwell A, et al.  Narcolepsy-cataplexy. II. Psychosocial consequences and associated psychopathology. Arch Neurol. 1982;39:169–171
  6. Green PM, Stillman MJ. Narcolepsy. Signs, symptoms, differential diagnosis, and management. Arch Fam Med. 1998;7:472–478
  7. Guilleminault C. Narcolepsy syndrome. In:  Kryger MN,  Roth T,  Dement WC editor. Principles and practice of sleep medicine. Philadelphia, PA: W.B. Saunders; 1994;p. 549–561
  8. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep. 1994;17:352–371
  9. Hoffman BB, Lefkowitz RJ. Carecholamines. sympthathomimetic drugs, and adrenergenic receptor antogonists. In:  Hardman JG,  Limbird LE,  Molinoff PB,  Ruddon RW,  Gilman AG editor. Goodman & Gilman's the pharmacologic basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996;p. 199–248
  10. In:  Parkes JD,  Guilleminault C,  Dement WC,  Pasouant P editor. Narcolepsy. New York: Spectrum; 1976;p. 644–658
  11. Modafinil US  Narcolepsy Multicenter Study Group . Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol. 1998;43:88–97
  12. Modafinil US  Narcolepsy Multicenter Study Group . Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology. 2000;54:1166–1175
  13. Carskadon MA, Dement WC, Mitler MM, Roth T, et al.  Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep. 1986;9:519–524
  14. Mitler MM, Gujavarty KS, Browman CP. Maintenance of wakefulness test: a polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. Electroenceph clin Neurophysiol. 1982;53:658–661
  15. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: National Institute of Mental Health, US Department of Health, Education, and Welfare; 1976;
  16. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540–545
  17. Narcolepsy. The International classification of sleep disorders diagnostic and coding manual. Rochester: American Sleep Disorders Association, 1990. pp. 38–49.
  18. Ware JE. SF-36 health survey. Manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center; 1993;
  19. McHorney CA, Ware JE, Lu JFR, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32:40–66
  20. McHorney CA, Ware JE, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical test of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–263
  21. Aloe F, Pedroso A, Tavares SM. Epworth Sleepiness Scale outcome in 616 Brazilian medical students. Arq Neuropsiquiatr. 1997;55:220–226
  22. Whitney CW, Enright PL, Newman AB, Bonekat W, et al.  Correlates of daytime sleepiness in 4578 elderly persons: the Cardiovascular Health Study. Sleep. 1998;21:27–36
  23. Maycock G. Sleepiness and driving: the experience of heavy goods vehicle drivers in the UK. J Sleep Res. 1997;6:238–244
  24. Johns M, Hocking B. Daytime sleepiness and sleep habits of Australian workers. Sleep. 1997;20:844–849
  25. Beusterien KM, Rogers AE, Walsleben JA, Emsellem HA, et al.  Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep. 1999;22:757–765
  26. Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache. 1995;35:449–454
  27. Beusterien KM, Nissenson AR, Port FK, Kelly M, et al.  The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7:763–773
  28. Make B, Glenn K, Ikle D, Bucher B, et al.  Pulmonary rehabilitation improves the quality of life of subjects with chronic obstructive pulmonary disease (COPD). Am Rev Respir Dis. 1992;145:A767
  29. PROVIGIL® (modafinil) Package Insert. March 1999. Cephalon, Inc., West Chester, PA. Available at: http://www.provigil.com.

PII: S1389-9457(00)00031-9

Sleep Medicine
Volume 1, Issue 3 , Pages 231-243 , 1 July 2000

Article Tools

* Image Usage & Resolution